PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executi
Biotechnology, Pharmaceuticals, Health
2026-03-30 3:00 AM EDT | PreveCeutical Medical Inc.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's
Biotechnology, Pharmaceuticals
2026-03-27 5:05 PM EDT | InMed Pharmaceuticals
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. -
2026-03-27 6:00 AM EDT | OS Therapies
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced i
Biotechnology, Pharmaceuticals
2026-03-26 8:00 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*. VINIA's leadership position is driven by its clinically demonstrate
Biotechnology, Pharmaceuticals, Health
2026-03-26 7:30 AM EDT | BioHarvest Sciences Inc.
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases. Key fourth-quarter, full-year 2025, and recent corporate highlights include: Advanced KIO-301 from regulatory clearance to patient
Biotechnology, Pharmaceuticals
2026-03-25 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma
New York, New York--(Newsfile Corp. - March 25, 2026) - OS Therapies, Inc
2026-03-25 6:00 AM EDT | OS Therapies
TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box
Highlights Chinese patent officially granted by CNIPA on March 17, 2026 Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026 Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engag
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-24 7:00 AM EDT | TempraMed Technologies Ltd.
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the closing of its non-brokered private placement financing that has secured total gross proceeds of $2.1 million. The Company issued 13,762,659 units in
2026-03-24 7:00 AM EDT | Sernova Biotherapeutics
Envoy Medical Reports Full Year 2025 Financial Results
Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 million in debt Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully impla
Biotechnology, Healthcare and Hospitals
2026-03-23 8:30 AM EDT | Envoy Medical, Inc.
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of di
Biotechnology, Pharmaceuticals
2026-03-23 7:30 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation addressing its lead product candidate, PH-762, will be given in the American Academy of Dermatology's Late-Breaking Research Session S034 on March 28, 2026 in Denver, Col
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
Defence Therapeutics Announces Warrant Terms Amendment
Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and th
Biotechnology, Pharmaceuticals, Health
2026-03-20 6:00 PM EDT | Defence Therapeutics Inc.
MCI Capital Markets and AxialBridge to Deliver Integrated De-Risking and Capital Access Platform for Life Science Companies
Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - MCI Capital Markets ("MCI"), an award-winning team that empowers companies to confidently navigate the capital markets, today announced its partnership with AxialBridge, a global team that boosts the velocity to market for new therapeutic and diagnostic technologies (the "Partnership"). The Partnership aims to make complex science investable for Biotech, Medtech, and Pharma companies transitioning from technical valida
Agriculture, Biotechnology, Energy, Oil & Gas
2026-03-18 8:00 AM EDT | Market Climber Inc.
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims
2026-03-18 7:00 AM EDT | Marvel Biosciences Corp.
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
Calgary, Alberta--(Newsfile Corp. - March 17, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces that because of delays in the completion of its year-end audit, the Company anticipates it will be unable to meet the prescribed deadline of March 31, 2026 for filing of the following continuous disclosure documents (collectively, the "Annual Filings"): Annual Audited Financial Statements, Annual Information Form, and M
Technology, Biotechnology, Healthcare and Hospitals
2026-03-17 10:49 PM EDT | Resverlogix Corp.
BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the re
Biotechnology, Pharmaceuticals, Health
2026-03-17 8:30 AM EDT | BioHarvest Sciences Inc.
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action ("MOA") as to how Ruvidar® is
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-17 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-16 11:30 AM EDT | Phio Pharmaceuticals Corp.